Icosavax Toekomstige groei
Future criteriumcontroles 0/6
Icosavax is forecast to grow earnings and revenue by 20.9% and 64.5% per annum respectively while EPS is expected to grow by 27.1% per annum.
Belangrijke informatie
20.9%
Groei van de winst
27.1%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | 64.5% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 11 Jan 2024 |
Recente toekomstige groei-updates
Recent updates
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth
Jul 04Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?
Mar 10Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?
Oct 18Icosavax GAAP EPS of -$0.57
Aug 15Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones
Jul 28Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Jun 22Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Mar 24We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely
Oct 29Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 49 | -123 | -112 | 13 | 4 |
12/31/2025 | 1 | -144 | -126 | -130 | 5 |
12/31/2024 | N/A | -115 | -112 | -115 | 5 |
12/31/2023 | N/A | -102 | -87 | -90 | 5 |
9/30/2023 | N/A | -97 | -76 | -71 | N/A |
6/30/2023 | N/A | -97 | -79 | -70 | N/A |
3/31/2023 | N/A | -93 | -77 | -66 | N/A |
12/31/2022 | 1 | -92 | -73 | -62 | N/A |
9/30/2022 | 3 | -86 | -72 | -63 | N/A |
6/30/2022 | 4 | -99 | -60 | -55 | N/A |
3/31/2022 | 6 | -85 | -54 | -52 | N/A |
12/31/2021 | 8 | -67 | -40 | -39 | N/A |
9/30/2021 | 7 | -53 | -30 | -29 | N/A |
6/30/2021 | 6 | -25 | -23 | -22 | N/A |
3/31/2021 | 4 | -21 | -15 | -15 | N/A |
12/31/2020 | 2 | -19 | -14 | -14 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ICVX is forecast to remain unprofitable over the next 3 years.
Winst versus markt: ICVX is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: ICVX is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: ICVX is forecast to have no revenue next year.
Hoge groei-inkomsten: ICVX is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ICVX's Return on Equity is forecast to be high in 3 years time